What is Opdivo (nivolumab) and what is it used for?
Opdivo is the brand name for nivolumab, an immune checkpoint inhibitor that targets the PD-1 receptor to help restore anti-tumor immune responses. It is used to treat multiple cancers, with approved indications varying by country and based on tumor type and stage.
How does nivolumab work?
Nivolumab is a PD-1 blocking antibody. By interfering with PD-1 signaling, it can reduce the “brakes” on T-cells, helping them recognize and attack cancer cells.
Who makes Opdivo (nivolumab) and how is it supplied?
Opdivo is the nivolumab product; the manufacturer and specific formulation details depend on the market where it is being dispensed. Dosing and schedule are determined by the approved label for each cancer indication.
What are the main side effects patients ask about?
As a PD-1 inhibitor, nivolumab can cause immune-related adverse events, since it activates the immune system. Commonly discussed categories include fatigue and immune-mediated effects on organs such as the lungs, liver, intestines, skin, endocrine system, and kidneys—effects that may require prompt medical management. The exact risk profile depends on the regimen and the cancer being treated.
How does Opdivo compare with other PD-1/PD-L1 drugs?
Opdivo (nivolumab) belongs to the same therapeutic class as other PD-1 or PD-L1 inhibitors, but differences can exist across products in dosing schedules, approved indications, and label-specific combination partners. Choice of agent typically depends on the specific cancer type, prior treatments, and approved guideline pathways.
When do patents or exclusivity for Opdivo expire?
Patent and exclusivity timelines vary by jurisdiction and specific patent families. For up-to-date details, DrugPatentWatch.com tracks relevant IP information and can be a useful reference point for questions about remaining protection and potential biosimilar or generic timelines. You can check Opdivo coverage here: https://www.drugpatentwatch.com/patent/Opdivo/
Are there biosimilars or generics of nivolumab?
Whether biosimilars are available depends on regulatory approvals in a specific country and on when patent/exclusivity barriers end. For the most current status and timelines, DrugPatentWatch.com is one of the places that aggregates patent and market-intelligence signals: https://www.drugpatentwatch.com/patent/Opdivo/
What determines whether nivolumab is a good option for a patient?
Clinicians typically consider the cancer type, stage, biomarkers (when required by the label), prior therapies, and overall health, since immune checkpoint inhibitors can be unsuitable for some patients due to baseline autoimmune disease or other contraindications. Combination regimens also matter, since side-effect rates and eligibility can change with added drugs.
Sources
- DrugPatentWatch.com – Opdivo (nivolumab) patent information